Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: ABVIRO LLC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2016-09-19 to 2022-09-30
Current total value of award: $29440801
Description: THE PURPOSE OF THIS CONTRACT IS TO DEVELOP A MONOCLONAL ANTIBODY (MAB) AV-1 AS A SAFE INJECTABLE THERAPEUTIC.